Summit Therapeutics IDWeek 2021 E-Poster Provides Enhanced Details About the Newly Discovered Novel Mechanism of Action of Ridinilazole

Summit Therapeutics today displaying an important e-Poster at IDWeek 2021. IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

Summit’s e-Poster provides enhanced details regarding the newly discovered novel mechanism of action of ridinilazole. The e-Poster will be available throughout IDWeek 2021, which takes place between September 29 and October 3, 2021.

Ridinilazole is Summit Therapeutics’ investigational first-in-class drug that recently completed enrollment of a Phase III clinical trial, Ri-CoDIFy. The primary endpoint of this trial seeks to demonstrate the superiority of ridinilazole in sustained clinical response as compared to vancomycin. Ridinilazole is not currently approved for use by any regulatory authority.

Summit’s poster presentation provides demonstrable scientific evidence of ridinilazole’s novel mechanism of action which involves binding to the minor groove of Clostridioides difficile bacteria’s DNA (the minor groove is a location on the helix of the bacteria’s DNA to which a drug can attach or bind). This is believed to be the primary mechanism through which ridinilazole elicits its bactericidal action against C. difficile bacteria. Ridinilazole has a novel mechanism of action and is the first of a new class of antibiotics: this is consistent with the World Health Organization’s (WHO) recommendation for developing antibiotics with novel mechanisms of action or that are new classes of drugs, which it considers a key point in overcoming existing bacterial resistance.1

Our updated research, through collaboration with the University of Houston, provides new images from high-resolution confocal microscopy. This technique has allowed intracellular visualization of ridinilazole binding to DNA within C. difficile and confirms this novel mechanism of action. Ridinilazole, if approved, has the potential to be the first antibiotic with a novel mechanism of action approved in over ten years.

The poster is available within the “Scientific Literature & Publications” section of our website:

About Summit Therapeutics

The overriding objective of Summit Therapeutics is to create value for patients, hospital caregivers, and community-based healthcare providers, as well as healthcare payers around the world. We seek to create value by developing drugs with high therapeutic efficacy – curing the cause of the patient’s condition with minimal or zero disease recurrence or antimicrobial resistance, for the longest extent possible – and minimizing the trauma caused to the patient and healthcare ecosystem by minimizing serious side effects, disease recurrence, and inaccessibility to our treatments as a result of financial or other barriers. Summit Therapeutics, empowered by its Discuva Platform, the Company’s innovative antibiotic discovery engine, and supported by BARDA and CARB-X funding, intends to be the leader in patient-friendly and paradigm-shifting treatments for infectious diseases and other significant unmet medical needs while being an ally to physicians. Our new mechanism pipeline product candidates are designed with the goal to become the patient-friendly, new-era standard of care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious diseases, initially focusing on Clostridioides difficile infection (CDI). Currently, Summit’s lead product candidate, ridinilazole, is a novel, first-in-class drug engaged in a global Phase III trial program versus vancomycin, for use as first-line therapy for the treatment of initial and recurrent Clostridioides difficile infection, and to show superiority in sustained clinical response. Commercialization of ridinilazole is subject to regulatory approvals. SMT-738, the second candidate within Summit’s portfolio, is currently in the IND-enabling phase for the treatment of multidrug resistant infections, specifically those caused by carbapenem-resistant Enterobacteriaceae (CRE).

To read the press release in its entirety, please click on the following link to be redirected.

Thank you.